✦ LIBER ✦

52 A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis

✍ Scribed by H.L.Y. Chan; C.L. Lai; M. Cho; J. Heathcote; Y.-M. Moon; Y.-C. Chao; R. Myers; G. Minuk; P. Marcellin; L. Jeffers; W. Sievert; R. Kaiser; G. Chao; N. Brown

Book ID: 117374334
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 245 KB
Volume: 44
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(06)80053-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

[54] PEGINTERFERON-ALPHA-2a PLUS ADEFOVI

[54] PEGINTERFERON-ALPHA-2a PLUS ADEFOVIR VS. PEGINTERFERON ALPHA-2a FOR 48 WEEKS IN HBeAg-NEGATIVE CHRONIC HEPATITIS B: PRELIMINARY 24-WEEK RESULTS OF THE PEG FOR B RANDOMIZED MULTICENTER TRIAL

✍ P. Piccolo; I. Lend; D. Di Paolo; C. Telesca; L. DeMelia; O. Sorbello; F. Bandie 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 143 KB

[516] A RANDOMIZED TRIAL OF SWITCHING TO

[516] A RANDOMIZED TRIAL OF SWITCHING TO TELBIVUDINE VERSUS CONTINUED LAMIVUDINE IN ADULTS WITH CHRONIC HEPATITIS B: RESULTS OF THE PRIMARY ANALYSIS AT WEEK 24

✍ R. Safadi; Q. Xie; Y. Chen; Y.-K. Yin; L. Wei; S.G. Hwang; E. Zuckerman; J.-D. T 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 276 KB

72 TENOFOVIR DISOPROXIL FUMARATE (TDF) F

72 TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B: WEEK 72 TDF DATA AND WEEK 24 ADEFOVIR DIPIVOXIL SWITCH DATA (STUDY 103)

✍ J. Heathcote; J. George; S. Gordon; J.P. Bronowicki; J. Sperl; R. Williams; P. M 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 58 KB

A 24-week, parallel-group, open-label, r

A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients

✍ Ming-Hua Zheng; Ke-Qing Shi; Zhi-Juan Dai; Chao Ye; Yong-Ping Chen 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 136 KB

PGI24 Cost-Effectiveness Analysis of 48-

PGI24 Cost-Effectiveness Analysis of 48-Week Peginterferon Alpha-2a Under RGT Strategy Versus 3 Years Entecavir for the Treatment of HBeAg-Positive Chronic Hepatitis B in China

✍ W. Zhang; H. Zhuang; H. Ren; X. Dou; W. Chen 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

GS-98-437 a double-blind, randomized, pl

GS-98-437 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results: Patrick Marcellin, Hopital Beaujon, Clichy France; Ting-Tsung Chang, National Cheng Kung Univ Hospital, Tainan Taiwan; Seng Gee Lim, National University Hospital, Singapore Singapore; Myron J Tong, Huntington Memorial Hospital, Pasadena, CA; William Sievert, Monash Medical Centre, Clayton, Victoria Australia; Mitchell Shiffman, McGuire VAMC, Richmond, VA; Lennox Jeffers, University of Miami, Miami, FL; Zack Goodman, Armed Forces Institute of Pathology, Washington, DC; Jia Ma, Anant Jain, John Fry, Carol L Brosgart, Gilead Sciences, Foster City, CA

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB